SEC Tracker
Get the app

Liquidia LQDA

Liquidia reports Q3 2026 financial results

Liquidia (LQDA) filed an 8-K with the SEC on Nov 10, 2026, 7:01 am ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results, Item 8.01 Other events

Form
8-K
Filed
Importance
Major
  1. YUTREPIA net product sales of $222.7 million in Q3 2026, up 31% from Q2 2026
  2. Recorded net loss of $236.3 million due to a $389.7 million litigation settlement charge
  3. Total patient shipments reached highest monthly level since launch in October 2026
  4. FDA granted Fast Track designation to YUTREPIA for SSc-RP treatment

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Liquidia files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.